New York, New York – (Newsfile Corp. – October 29, 2021) – Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies SA (“DBV” or the “Company”) (NASDAQ: DBVT). These investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The purpose of the investigation is to determine whether Ampli and any of its officers and / or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On October 26, 2021, DBV revealed that it had “received a communication from the FDA [U.S. Food and Drug Administration] regarding [DBV’s] Submission of the STAMP protocol of May 6, 2021. “DBV has informed the investors that”[t]The FDA has requested a phased approach to DBV’s Modified Viaskin Peanut (mVP) development program. The FDA would like to review data from the DBV protein uptake release study before providing additional comments on the design of the STAMP protocol. “
Following this news, the DBV share price fell $ 1.45 per share, or 28.71%, to close at $ 3.60 on October 27, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as the Dean of the Class Actions Bar, Pomerantz was a pioneer in the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breach of fiduciary duty and professional misconduct. The firm has recovered numerous multi-million dollar damages on behalf of the members of the group. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101394